Aronson A S, Svenningsen N W
Arch Dis Child. 1974 Aug;49(8):654-9. doi: 10.1136/adc.49.8.654.
A new method for the estimation of the renal capacity to concentrate urine is described. Intranasal administration of DDAVP (1-deamino-8-D-arginine vasopressin), a synthetic analogue of the antidiuretic hormone, has been used for the measurement of urine concentrating performance in 79 children and 25 infants. By comparative studies of different doses of intravenous and intranasal administration of DDAVP, a standard procedure has been elaborated with the intranasal administration of 20 μg in children and 10 μg in infants. The maximum urine osmolality values obtained with the DDAVP test are compared to those achieved with other renal concentration tests, i.e. dehydration test and pitressin test. The present investigation shows that intranasal administration of DDAVP, with no or only moderate short-term fluid restriction, yields urine osmolality values comparable to those after 22 hours of prolonged dehydration, and higher than those after combined pitressin and fluid deprivation test. No side effects have been observed with the procedure described.
本文描述了一种估算肾脏浓缩尿液能力的新方法。抗利尿激素的合成类似物去氨加压素(1-去氨基-8-D-精氨酸加压素)经鼻内给药,已用于79名儿童和25名婴儿的尿液浓缩功能测量。通过对不同剂量静脉注射和鼻内注射去氨加压素的对比研究,制定了一个标准程序,即儿童鼻内注射20μg,婴儿鼻内注射10μg。将去氨加压素试验获得的最大尿渗透压值与其他肾脏浓缩试验(即脱水试验和垂体后叶素试验)所获得的值进行比较。目前的研究表明,在无或仅适度短期限液的情况下经鼻内给予去氨加压素,所产生的尿渗透压值与延长脱水22小时后的尿渗透压值相当,且高于垂体后叶素与禁水联合试验后的尿渗透压值。所描述的程序未观察到副作用。